Table 1 The clinical trials of next generation of CAR-T cells in cancer immunotherapy

EGFRt + cetuximab

CD19

NCT02028455

CD19⁺ acute leukemia

Anti-CD19 CAR-T/EGFRt

I/II

Recruiting

Seattle Children’s Hospital

To study the MTD and efficacy of CAR-T cells

NCT02146924

High-risk ALL

Anti-CD19 CAR-T/EGFRt

I

Recruiting

City of Hope Medical Center

To study the side effects and best dose of CAR-T cells

NCT01815749

Recurrent or high-risk NHL

Anti-CD19 CAR-T/EGFRt +auto-HSCT

I

Active, not recruiting

City of Hope Medical Center

To study the side effects and best dose of CAR-T cells

NCT03579888

CD19⁺ lymphoid malignancies

Anti-CD19 CAR-T/EGFRt +Cyclophosphamide +Fludarabine

I

Not yet recruiting

M.D. Anderson Cancer Center

To study the side effects and best dose of CAR-T cells

NCT02051257

Recurrent B-cell NHL

Anti-CD19 CAR-T/EGFRt

I

Active, not recruiting

City of Hope Medical Center

To study the highest dose of memory enriched T cells

NCT01865617

R/R CLL, NHL or ALL

Anti-CD19 CAR-T/EGFRt

I/II

Recruiting

Fred Hutchinson Cancer Research Center

To study the side effects and best dose of CAR-T cells

NCT03103971

R/R B-Cell NHL or ALL

Anti-CD19 CAR-T/EGFRt +Cyclophosphamide

+Fludarabine

I

Recruiting

Fred Hutchinson Cancer Research Center

To study the side effects of CAR-T cells

NCT03085173

R/R CLL

Anti-CD19 CAR-T/EGFRt

I

Recruiting

Memorial Sloan Kettering Cancer Center

To study the MTD of CAR-T cells

CD123

NCT02159495

CD123⁺ R/R AML and persistent/recurrent BPDCN

Anti-CD123 CAR-T/EGFRt

+Fludarabine

I

Recruiting

City of Hope Medical Center

To study the side effects and the best dose of CAR-T cells

NCT03114670

Recurrent AML after allo-HSCT

Anti-CD123 CAR-T/EGFRt

I

Recruiting

Affiliated Hospital to Academy of Military Medical Sciences

To study the safety and effectiveness of CAR-T cells

CD22

NCT03244306

CD22⁺ leukemia

Anti-CD22 CAR-T/EGFRt

I

Active, not recruiting

Seattle Children’s Hospital

To study the safety and feasibility of CAR-T cells

CD171

NCT02311621

Neuroblastoma

Anti-CD171 CAR-T/EGFRt

I

Recruiting

Seattle Children’s Hospital

To study the MTD of CAR-T cells

EGFR

NCT03618381

R/R solid tumors

Anti-EGFR CAR-T/EGFRt

I

Recruiting

Seattle Children’s Hospital

To study the safety, feasibility, and efficacy of CAR-T cells

HER2

NCT03500991

HER2⁺ R/R pediatric CNS tumors

Anti-HER2 CAR-T/EGFRt

I

Recruiting

Seattle Children’s Hospital

To study the safety and feasibility of CAR-T cells via an indwelling CNS catheter

BCMA

NCT03070327

Multiple myeloma

Anti-BCMA CAR-T/EGFRt +Cyclophosphamide

+Lenalidomide

I

Recruiting

Memorial Sloan Kettering Cancer Center

To study the safety of CAR-T cells

iCasp9+

AP1903

GD2

NCT01822652

Neuroblastoma

Anti-GD2 CAR-T/iCasp9

I

Active, not recruiting

Baylor College of Medicine

To study the highest dose of CAR-T cells

NCT01953900

GD2⁺

osteosarcoma

neuroblastoma

Anti-GD2 CAR-T/iCasp9

I

Recruiting

Baylor College of Medicine

To study the largest safe dose of CAR-T cells

NCT02107963

GD2⁺ solid tumors

Anti-GD2 CAR-T/iCasp9

+Cyclophosphamide

I

Completed

National Cancer Institute

No results posted

NCT03721068

Neuroblastoma

Anti-GD2 CAR-T/IL-15/iCasp9 + Fludarabine

+Cyclophosphamide

I

Recruiting

UNC Lineberger Comprehensive Cancer Center

To study the safety and feasibility of CAR-T cells

CD19

NCT03016377

R/R ALL

Anti-CD19 CAR-T/iCasp9

+Cyclophosphamide +Fludarabine

I

Recruiting

UNC Lineberger Comprehensive Cancer Center

To study the safety and feasibility of CAR-T cells, and the optimal dose of AP1903

NCT03696784

R/R B-cell lymphoma

Anti-CD19 CAR-T/iCasp9 + Bendamustine

+Fludarabine

I

Not yet recruiting

UNC Lineberger Comprehensive Cancer Center

To study the safety and feasibility of CAR-T cells

CD19

CD22

NCT03098355

B-cell leukemia

and lymphoma

Anti-CD19/22 CAR-T/iCasp9 + IL-2

I/II

Recruiting

Zhujiang Hospital

To study the safety, efficacy and persistence of CAR-T cells

CD30

NCT02274584

CD30⁺ lymphomas

Anti-CD30 CAR-T/iCasp9

I/II

Recruiting

Peking University

To study the safety of CAR-T cells

Mesothelin

NCT02414269

Mesothelioma, lung cancer or breast cancer

Anti-mesothelin CAR-T/iCasp9 + Cyclophosphamide

I

Recruiting

Memorial Sloan Kettering Cancer Center

To study the safety of CAR-T cells

TanCAR

CD19

CD20

NCT03019055

R/R CD19⁺ or CD20⁺ B-cell malignancies

Anti-CD19/20 CAR-T cells

I/II

Recruiting

Medical College of Wisconsin

To study the safety and feasibility of CAR-T cells

NCT03097770

R/R B-cell leukemias and lymphomas

Anti-CD19/20-CAR-T cells

NA

Recruiting

Chinese PLA General Hospital

To study the safety and feasibility, and the duration of in vivo survival of tanCART-19/20 cells